bDNA-based Alu quantitative assay of plasma cell-free DNA level in sepsis patients

Abstract

Abstract: Objective　To investigate the significance of plasma cell-free DNA（cf-DNA） in diagnosis of sepsis and differential diagnosis between sepsis and systemic inflammatory response syndrome（SIRS）. Methods　The plasma cf-DNA of 24 sepsis patients，43 SIRS patients and 73 healthy controls were detected by bDNA-based Alu quantitative assay. Receiver operating characteristic（ROC） curve was performed to evaluate the clinical significance of plasma cf-DNA. Results　The plasma cf-DNA significantly increased in sepsis patients compared with in SIRS patients and healthy controls [1 398.96（19.28-2 987.56）g/mL，609.67（15.98-2 596.87）ng/mL and 68.56（12.56-309.78）ng/mL，respectively，P＜0.001]. The areas under the ROC curve（AUC） of cf-DNA for the SIRS patients with healthy controls，sepsis patients with healthy controls and sepsis patients with SIRS patients were 0.763（0.661-0.865），0.955（0.884-1.025） and 0.777（0.663-0.891），respectively. Conclusions　Plasma cf-DNA has a clinical significance as a new biomarkerfor the diagnosis of sepsis.

Key words: 〖WTBZ〗Cell-free DNA, bDNA-based Alu quantitative assay, Biomarker, Sepsis, Diagnosis

HOU Yanqiang，LIANG Dongyu，PENG Liang，LOU Xiaoli，LIU Tao，CHEN Hongwei. bDNA-based Alu quantitative assay of plasma cell-free DNA level in sepsis patients[J]. , 2012, 27(12): 1050-1053.

References

[1]Martin GS，Mannino DM，Eaton S，et al. The epidemiology of sepsis in the United States from 1979 through 2000[J]. N Engl J Med，2003，348（16）:1546-1554.
[2]Eissa DS，El-Farrash RA. New insights into thromb-opoiesis in neonatal sepsis[J]. Platelets，2012 Jul 2[Epub ahead of print].
[3]Schwetz I，Hinrichs G，Reisinger EC，et al. Delayed processing of blood samples influences time to positivity of blood cultures and results of Gram stain-acridine orange leukocyte Cytospin test[J]. J Clin Microbiol，2007，45（8）:2691-2694.
[4]Wagner J.free DNA-new potential analyte in clinical laboratory diagnostics[J]. Biochem Med（Zagreb），2012，22（1）:24-38.
[5]拜红霞. 血清游离DNA在肿瘤诊断中的研究进展[J]. 检验医学与临床，2011，8（9）:1110-1112.
[6]Herzum I，Renz H. Inflammatory markers in SIRS，sepsis and septic shock[J]. Curr Med Chem，2008，15（6）:581-587.
[7]BozzafA，Salluh JI，Japiassu AM，et al. Cytokine profiles as markers of disease severity in sepsis：a multiplex analysis[J]. Crit Care，2007，11（2）：R49.
[8]Oconnor E，Venkatesh B，Mashongonyika C，et al. Serum procalciton in and C-reactive protein as markers of sepsis and outcome in patients with neurotrauma and subarachnoid haemorrhage[J]. Anaesth Intensive Care，2004，32（4）：465-470.
[9]Riedel S. Procalcitonin and the role of biomarkers in the diagnosis and managementof sepsis[J]. Diagn Microbiol InfectDis，2012，73（3）:221-227.
[10]Uusitalo-Seppl R，Koskinen P，Leino A，et al. Early detection of severe sepsis in the emergency room：diagnostic value of plasma C-reactive protein，procalcitonin，and interleukin-6[J]. Scand J InfectDis，2011，43（11-12）:883-890.
[11]Ugarte H，Silva E，Mercan D，et al. Procalcitonin used as a marker of infection in the intensive care unit[J]. CritCare Med，1999，27（3）:498-504.
[12]Tang BM，Eslick GD，Craig JC，et al. Accuracy of procalcitonin for sepsis diagnosis in critically ill patients：systematic review and meta-analysis[J]. LancetInfectDis，2007，7（3）：210-217.
[13]Pierrakos C，Vincent JL. Sepsis biomarkers：a review[J]. Crit Care，2010，14（1）:R15.
[14]娄晓丽，侯彦强. 分支链DNA信号放大技术及其在临床医学中的研究应用[J]. 世界肿瘤杂志，2010，9（3- 4）:180-183.
[15]孙群，王德生. 游离DNA与临床肿瘤的研究进展[J]. 医学综述，2010，16（9）:1348-1350.
[16]Deligezer U，Eralp Y，Akisik EE，et al. Size distribution of circulating cell-free DNA in sera of breastcancer patients in the course of adjuvant chemotherapy[J]. Clin Chem Lab Med，2008，46（3）:311-317.
[17]Wheeler DS. Death to sepsis：targeting apoptosis pathways in sepsis[J]. Crit Care，2009，13（6）:1010.
[18]Ayala A，Perl M，Venet F，et al. Apoptosis in sepsis：mechanisms，clinical impact and potential therapeutic targets[J]. Curr Pharm Des，2008，14（19）:1853-1859.